Vaidya Sane Ayurved Laboratories Q4 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹143 Cr
- P/E
- 15.94
- ROE
- 11.99%
- PEG
- 0.70
- Price to sales
- 1.34
- Debt to equity
- 0.03
- 52W high / low
- ₹288 / ₹136
- EBITDA margin
- 14.42%
- Net profit margin
- 8.41%
- Promoter holding
- 66.34%
- Sales (last year)
- ₹107 Cr
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running of hospitals & clinics, and sale of Ayurved based medicines[1]
Guidance scorecard · Q4 FY26 call
What Vaidya Sane Ayurved Laboratories Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies
Healthcare Equipment & Supplies
RevenueQ4 FY26 call
10–20%- FY'27 revenue target: Rs. 170-180 crores driven by higher patient additions, increased hospital utilization, and franchise clinic growth.
- Medium-term target (FY'28): Scale revenues towards Rs. 250-300 crores with about 50% of revenue coming from hospitals.
- Clinic revenue projected at Rs. 100-110 crores; hospital revenue Rs. 50-60 crores in FY'27.
- Patient inflow expected to grow steadily; marketing efforts focused on acquiring ~200,000 new patients annually by FY'28.
- ARPU growth expected to be marginal (5-10%) with single-digit ARPU growth in hospital segment.
- Expansion in hospital beds (e.g., Khopoli hospital to 150 beds by FY'28) supports revenue growth.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
Up 2%+See what Vaidya Sane Ayurved Laboratories Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Preferential allotment funds received are currently in Fixed Deposit (FD) and have not been utilized yet; expected full funding to arrive over about 12 months.
- Planned Capex includes ongoing construction for expansion, particularly at the Khopoli hospital, currently at the third slab out of seven, aiming to complete before the upcoming rainy season.
- Expansion plans also include Nagpur hospital, pending government permissions, and future bed additions across hospitals to target 250-300 beds.
- Strategic investment via proposed acquisition of Parasnath Health Care OPC Private Limited to expand healthcare capabilities and integrated ecosystem.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
PlannedSee what Vaidya Sane Ayurved Laboratories Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
- The company is focusing on growing patient inflows, aiming for approximately 2 lakh new patients in FY’28.
- Expansion plans include operationalizing around 140-150 additional hospital beds by March 2027.
- Revenue targets are set at Rs. 170 to Rs. 180 crore for FY’27 and Rs. 250 to Rs. 300 crore by FY’28.
2 more points from Vaidya Sane Ayurved Laboratories Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Flat | ₹627 Cr | 21.4 | |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | Vaidya SaneThis stock | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track Vaidya Sane Ayurved Laboratories Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingFinancials of Vaidya Sane Ayurved Laboratories Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Vaidya Sane Ayurved Laboratories Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of Vaidya Sane Ayurved Laboratories Ltd
Profit & Loss
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 99 | 99 | 90 | 107 |
| Expenses + | 91 | 95 | 76 | 91 |
| Operating Profit | 9 | 5 | 13 | 15 |
| OPM % | 9% | 5% | 15% | 14% |
| Other Income + | 1 | 2 | 1 | 2 |
| Interest | 1 | 0 | 0 | 1 |
| Depreciation | 3 | 3 | 4 | 6 |
| Profit before tax | 6 | 3 | 10 | 11 |
| Tax % | 25% | 30% | 28% | 17% |
| Net Profit + | 5 | 2 | 7 | 9 |
| EPS in Rs | 4.59 | 1.88 | 6.80 | 8.55 |
| Dividend Payout % | 5% | 0% | 0% | 0% |
Financials of Vaidya Sane Ayurved Laboratories Ltd
Balance Sheet
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 |
| Reserves | 30 | 45 | 52 | 77 |
| Borrowings + | 0 | 2 | 1 | 3 |
| Other Liabilities + | 14 | 12 | 13 | 14 |
| Total Liabilities | 55 | 70 | 77 | 105 |
| Fixed Assets + | 21 | 28 | 34 | 35 |
| CWIP | 2 | 2 | 1 | 2 |
| Investments | 15 | 18 | 21 | 40 |
| Other Assets + | 17 | 21 | 20 | 28 |
| Total Assets | 55 | 70 | 77 | 105 |
Financials of Vaidya Sane Ayurved Laboratories Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -1 | 11 | 5 |
| Cash from Investing Activity + | 1 | -13 | -10 | -24 |
| Cash from Financing Activity + | -1 | 15 | -1 | 17 |
| Net Cash Flow | -1 | 1 | -0 | -2 |
| Free Cash Flow | -7 | -12 | 2 | -2 |
| CFO/OP | 31% | -9% | 93% | 49% |
Financials of Vaidya Sane Ayurved Laboratories Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 22 | 22 | 31 | 35 |
| Inventory Days | 58 | 82 | 70 | |
| Days Payable | 101 | 149 | 127 | |
| Cash Conversion Cycle | 22 | -20 | -37 | -21 |
| Working Capital Days | -2 | 5 | 7 | 112 |
| ROCE % | 6% | 18% | 15% |
Guidance history
How Vaidya Sane Ayurved Laboratories Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 10–20% | Up 2%+ | Planned | Planned | — |
| Q2 FY26 call → | 20–40% | Up 2%+ | Planned | Planned | Rising |
| Q4 FY25 call → | 20–40% | Flat | Planned | — | — |
| Q2 FY25 call → | 0–10% | Up 2%+ | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Vaidya Sane Ayurved Laboratories Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec